ERBB2 and breast cancer: The PerELISA and PAMELA studies, in particular, provided valuable insights by demonstrating that patients with the HER2-E subtype of HR+/HER2+ breast cancer, as classified by PAM50, exhibited significantly higher pCR rates compared to other subtypes.